Form 4: Adverum Biotechnologies Executive Acquires 130,000 Shares Through Stock Option Vesting

Peter Soparkar, Chief Operating Officer of Adverum Biotechnologies, acquired 130,000 shares through the vesting of performance stock options.

Summary

• Peter Soparkar, the Chief Operating Officer of Adverum Biotechnologies, acquired 130,000 shares of common stock through the vesting of stock options.
• The transaction occurred on October 3, 2023, as a result of meeting a performance condition related to the LUNA trial.
• The Compensation Committee certified that the Vesting Commencement Date occurred on August 16, 2023.
• The options vest monthly, with full vesting occurring on the second anniversary of the Vesting Commencement Date, contingent upon continued service.
• The exercise price of the stock options is $1.29.
• Following the transaction, Soparkar directly owns 130,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The vesting of stock options indicates that performance conditions were met, but it's a routine event and doesn't necessarily signal a major shift in the company's prospects.

Positives

• The vesting of stock options suggests that performance conditions related to the LUNA trial were met, which could be viewed positively.
• The continued service requirement for vesting aligns the executive's interests with the company's long-term success.

Future Outlook

The stock options will continue to vest monthly until the second anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer.

Industry Context

Executive stock option grants and vesting are common practices in the biotechnology industry to incentivize and retain key personnel. The vesting schedule tied to performance metrics, such as the LUNA trial, aligns executive compensation with the company's clinical development milestones.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies, such as Amgen, Gilead Sciences, and Biogen.
• Vesting schedules tied to performance milestones, such as clinical trial progress, are also common in the industry.
• The specific terms of the options, such as the exercise price and vesting schedule, would need to be compared to industry benchmarks to assess their competitiveness.

Stakeholder Impact

• The vesting of stock options could have a minor dilutive effect on existing shareholders.
• The vesting incentivizes the COO to continue working towards the company's success, which benefits shareholders.

Key Dates